TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11848259
Drug: Usual guidelines-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual guidelines-based treatment
Study: 9865735
Drug: All-trans retinoic
Normalized name: all trans Retinoic acid
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All-trans retinoic acid (RA) therapy
Study: 9865735
Drug: RA therapy
Normalized name: ALLANTOIN 0.5 g in 100 mL TOPICAL LOTION [ALRA THERAPY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: RA therapy after relapse
Study: 7833225
Drug: Intra-articular injection
Normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular injection of an aqueous solution containing paracetamol, salicylate, diclofenac, and [125I]-albumin (0.1 to 0.2 ml)
Study: 3122349
Drug: Mannitol (preoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mannitol (preoperative administration)
Study: 24649919
Drug: Montelukast 10
Normalized name: montelukast 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast 10 mg daily for 2 weeks
Study: 14598509
Drug: Hormone therapy
Normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hormone therapy by progestagens and antiestrogens
Study: 11304054
Drug: CHIK vaccine
Normalized name: CHIKUNGUNYA VACCINE
DrugBank: Chikungunya vaccine (live, attenuated) (DB18701)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHIK vaccine
Study: 1999706
Drug: MTX 200
Normalized name: MTX
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: MTX 200 mg/m2 followed by 5-FU 600 mg/m2 (arm A)
Study: 1999706
Drug: MTX 200
Normalized name: MTX
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: MTX 200 mg/m2 followed by 5-FU 600 mg/m2 (arm B)
Study: 6095656
Drug: H2-receptor antagonists
Normalized name: H2-receptor antagonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: H2-receptor antagonists (ranitidine and cimetidine)
Study: 27142078
Drug: Twice daily
Normalized name: CAPSULE, TWICE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily assisted exercise intervention (n = 13)
Study: 27142078
Drug: Once daily
Normalized name: GEL, ONCE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily assisted exercise intervention (n = 11)
Study: 25315942
Drug: Esmolol (beta-blocker)
DrugBank: Esmolol (DB00187)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Esmolol (beta-blocker)
Study: 21861845
Drug: ARB therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARB therapy (losartan, 100 mg/day)
Study: 12073199
Drug: Diltiazem (bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (bolus 0.25 mg/kg followed by continuous infusion of 1.7 microg/kg/min) (DTZ, n = 12)
Study: 9799972
Drug: Red ginseng
Normalized name: Red ginseng
DrugBank: Ginseng (DB01404)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red ginseng (4.5 g/day)
Study: 10759280
Drug: Glyceryl trinitrate
Normalized name: Glyceryl trinitrate
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glyceryl trinitrate spray
Study: 23024023
Drug: Directly Observed
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Directly Observed Inhaled Corticosteroid (DOICS) treatment with budesonide 1,600 μg for 7 days
Study: 23024023
Drug: Directly Observed
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Directly Observed Inhaled Corticosteroid (DOICS) treatment with budesonide 1,600 μg for 5 days
Study: 17627681
Drug: i.v. hydralazine
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. hydralazine (5 mg doses)
Study: 17627681
Drug: mini‐bolus diazoxide
Approvals — FDA: no, EMA: no, PMDA: no
Description: mini‐bolus diazoxide (15 mg doses)
Study: 12098159
Drug: Real low-level
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Real low-level laser therapy (LLLT) plus microamperes transcutaneous electric nerve stimulation (TENS)
Study: 12098159
Drug: Sham low-level
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham low-level laser therapy (LLLT) plus microamperes transcutaneous electric nerve stimulation (TENS)
Study: 7744087
Drug: Felodipine ER
Normalized name: Felodipine ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine ER 10 mg o.m.
Study: 7744087
Drug: Nifedipine SR
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine SR 20 mg b.d.
Study: 6271049
Drug: Cefotaxime (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotaxime (1.0 g) intramuscularly
Study: 6271049
Drug: Procaine penicillin
Normalized name: procaine penicillin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Procaine penicillin G (4.8 x 10(6) U) intramuscularly with 1 g of probenecid orally
Study: 30642667
Drug: No oral
Normalized name: Beano Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: No oral anticoagulation (non-OAC)
Study: 28256356
Drug: 3 weeks
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 weeks of intensive speech and language therapy (≥10 hours per week)
Study: 28256356
Drug: 3 weeks
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 weeks deferral of intensive speech and language therapy
Study: 21177034
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (weekly information on general health)
Study: 20355166
Drug: Testosterone (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone (250 mg Sustanon) administered weekly for five weeks
Study: 17855669
Drug: High-dose melphalan
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose melphalan plus autologous stem cells
Study: 17855669
Drug: Melphalan plus
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Melphalan plus high-dose dexamethasone
Study: 17855669
Drug: High-dose melphalan
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose melphalan plus autologous stem cells (low-risk disease)
Study: 17855669
Drug: Melphalan plus
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Melphalan plus high-dose dexamethasone (low-risk disease)
Study: 17855669
Drug: High-dose melphalan
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose melphalan plus autologous stem cells (high-risk disease)
Study: 17855669
Drug: Melphalan plus
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Melphalan plus high-dose dexamethasone (high-risk disease)
Study: 9559773
Drug: Cefepime (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefepime (2 g administered every 12 h)
Study: 9559773
Drug: Ceftriaxone (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone (1 g administered every 12 h)
Study: 3665393
Drug: Ibuprofen 400
Normalized name: ibuprofen 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 400 mg administered alone
Study: 3665393
Drug: Ibuprofen 400
Normalized name: ibuprofen 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 400 mg administered concurrently with antacid (62 mL of aluminum and magnesium hydroxide suspension)
Study: 3665393
Drug: Ibuprofen 400
Normalized name: ibuprofen 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 400 mg administered with antacid one hour after the ibuprofen dose
Study: 3665393
Drug: Ibuprofen 400
Normalized name: ibuprofen 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 400 mg administered concurrently with antacid plus three more antacid doses given every five hours
Study: 23542612
Drug: Topical ketoprofen
Normalized name: ketoprofen Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical ketoprofen 50 mg
Study: 23542612
Drug: Topical ketoprofen
Normalized name: ketoprofen Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical ketoprofen 100 mg
Study: 23542612
Drug: Ketoprofen-free vehicle
Normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketoprofen-free vehicle 2.2 g (TDT 064)
Study: 23542612
Drug: Ketoprofen-free vehicle
Normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketoprofen-free vehicle 4.4 g (TDT 064)
Study: 23542612
Drug: Oral celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral celecoxib 100 mg
Study: 18218783
Drug: Isoproterenol infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoproterenol infusion 1 (before fingolimod administration)
Study: 18218783
Drug: Fingolimod administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fingolimod administration
Study: 18218783
Drug: Isoproterenol infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoproterenol infusion 2 (in the presence of fingolimod)
Study: 18218783
Drug: Total isoproterenol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total isoproterenol dose with fingolimod
Study: 18218783
Drug: Isoproterenol infusions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoproterenol infusions 3 to 5
Study: 11701431
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist plus graded doses of testosterone
Study: 11701431
Drug: Control (GnRH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (GnRH agonist only)
Study: 9388519
Drug: RT and
Normalized name: Comfort and Ease KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: RT and daily low dose of CDDP (5 mg/m2)
Study: 8198916
Drug: Thiopentone 5.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopentone 5.1 mg kg‐1 with suxamethonium
Study: 8198916
Drug: Propofol 2.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 2.2 mg kg‐1 with suxamethonium
Study: 22338818
Drug: Oral health
Normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral health action plan including child's current caries-risk status, identification of issues of concern, and one goal to improve on for the next visit.
Study: 12749510
Drug: Granisetron/dexamethasone combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granisetron/dexamethasone combination (40 microg/kg granisetron + 8 mg dexamethasone)
Study: 9170120
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg micronized progesterone administered in the evening
Study: 8466015
Drug: 5 micrograms/mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 micrograms/mL norepinephrine
Study: 8466015
Drug: 10 micrograms/mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 micrograms/mL norepinephrine
Study: 8466015
Drug: 15 micrograms/mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 micrograms/mL norepinephrine
Study: 8466015
Drug: Plain tetracaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plain tetracaine (0 micrograms/mL norepinephrine)
Study: 31363043
Drug: Endovascular therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular therapy favored by female physicians under ideal conditions
Study: 31363043
Drug: Endovascular therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular therapy favored by male physicians under ideal conditions
Study: 31363043
Drug: Endovascular therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular therapy favored by female physicians under current local resources
Study: 31363043
Drug: Endovascular therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular therapy favored by male physicians under current local resources
Study: 31622158
Drug: β-alanine supplementation
Normalized name: Alanine
DrugBank: Alanine (DB00160)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: β-alanine supplementation (6.4 g/day) during HIIT
Study: 18989245
Drug: h‐ANP (human
Approvals — FDA: no, EMA: no, PMDA: no
Description: h‐ANP (human atrial natriuretic peptide) treatment, 0.02 microg/kg/min for 5 days or more
Study: 18989245
Drug: h‐ANP treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: h‐ANP treatment
Study: 18989245
Drug: non‐h‐ANP treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: non‐h‐ANP treatment (Group N)
Study: 10224212
Drug: Intraoral sucrose
Normalized name: Sucrose
DrugBank: Sucrose (DB02772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraoral sucrose (48% solution) before feeding
Study: 10224212
Drug: Intraoral sucrose
Normalized name: Sucrose
DrugBank: Sucrose (DB02772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraoral sucrose (48% solution) after feeding
Study: 10224212
Drug: Intraoral sucrose
Normalized name: Sucrose
DrugBank: Sucrose (DB02772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraoral sucrose (48% solution)
Study: 1877037
Drug: Budesonide (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide (200 micrograms twice daily) and terbutaline (500 micrograms four times daily)
Study: 7088766
Drug: 0.25 mg
Normalized name: biotin 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg ergotamine by injection (6 i.v. and 11 i.m.)
Study: 7088766
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg ergotamine by mouth
Study: 7088766
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg ergotamine by suppository
Study: 7088766
Drug: Plasma ergotamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma ergotamine levels exceeding 1.8 ng/ml
Study: 31172717
Drug: Budesonide inhalation
Normalized name: Budesonide Inhalation Powder
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide inhalation suspension (BIS) via transnasal nebulization
Study: 31172717
Drug: Budesonide nasal
Normalized name: budesonide nasal
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide nasal spray (BNS)
Study: 24282036
Drug: Two-step 50
Normalized name: zinc oxide
DrugBank: Zinc oxide (DB09321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Two-step 50 g Glucose Challenge Test (GCT)
Study: 24282036
Drug: 75 g
Normalized name: Zosyn 3.375 GM Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 g Glucose Tolerance Test (GTT)
Study: 18976320
Drug: Carbamazepine (subgroup
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbamazepine (subgroup of AED monotherapy)
Study: 3071266
Drug: Clindamycin (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindamycin (3 x 600 mg in 100 ml 0.9% saline)
Study: 3071266
Drug: Metronidazole (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole (3 x 500 mg in 100 ml 0.9% saline)
Study: 3071266
Drug: Placebo (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (3 x 100 ml of 0.9% saline)
Study: 23015618
Drug: Computer-controlled infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Computer-controlled infusion of phenylephrine (100 µg ml(‐1))
Study: 23015618
Drug: Manual-controlled infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Manual-controlled infusion of phenylephrine
Study: 23015618
Drug: Computer-controlled infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Computer-controlled infusion of phenylephrine
Study: 12833013
Drug: Clobetasol propionate
Normalized name: Clobetasol Propionate
DrugBank: Clobetasol propionate (DB01013)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Clobetasol propionate 0.05% foam plus vehicle spray
Study: 12833013
Drug: Clobetasol propionate
Normalized name: Clobetasol Propionate
DrugBank: Clobetasol propionate (DB01013)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Clobetasol propionate 0.05% foam plus 0.25% zinc pyrithione spray
Study: 10827212
Drug: 20 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 g/d FOS
Study: 1520648
Drug: Atenolol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (50 mg bid)
Study: 1520648
Drug: Nifedipine (20-40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (20-40 mg bid)
Study: 30773564
Drug: Interscalene brachial
Normalized name: Brachiara mutica pollen
DrugBank: Urochloa mutica pollen (DB10716)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interscalene brachial plexus block (group I) with 0.2% ropivacaine 10 mL
Study: 30773564
Drug: C5‐6 nerve
Approvals — FDA: no, EMA: no, PMDA: no
Description: C5‐6 nerve root block (group C) with 0.2% ropivacaine 10 mL
Study: 19372331
Drug: Propofol 1
Normalized name: propofol 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 1 mg/kg followed by an infusion of 2.5 mg x kg(‐1) x h(‐1) for 59 min
Study: 19372331
Drug: Midazolam (C(blood):
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (C(blood): 225 ng/mL)
Study: 16894336
Drug: Low-dose EPT
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose EPT (1 mg 17beta-estradiol + 0.5 mg norethisterone acetate)
Study: 16894336
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (T and low-dose EPT)
Study: 15136349
Drug: Rectal-contrast CT
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal-contrast CT scan
Study: 11280073
Drug: Polonga TAb
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polonga TAb (1 g)
Study: 11280073
Drug: Haffkine antivenom
Normalized name: ANTIVENIN,CROTALIDAE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haffkine antivenom (10 g)
Study: 29617982
Drug: 1500 mg
Normalized name: inulin 1500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1500 mg single oral dose of gepotidacin
Study: 29617982
Drug: 3000 mg
Normalized name: talc 3000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3000 mg single oral dose of gepotidacin
Study: 29617982
Drug: Combined dose
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined dose groups (1500 mg and 3000 mg)
Study: 26020712
Drug: Vortioxetine 15-20
Normalized name: vortioxetine 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vortioxetine 15-20 mg
Study: 12764691
Drug: Thiopental 5‐7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopental 5‐7 mg/kg IV
Study: 12764691
Drug: Etomidate 0.2‐0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etomidate 0.2‐0.3 mg/kg IV
Study: 1589135
Drug: L-sulpiride (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-sulpiride (75 mg die per os)
Study: 1589135
Drug: Metoclopramide (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide (30 mg die per os)
Study: 6112039
Drug: Pirbuterol (beta
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirbuterol (beta agonist with vasodilator and positive inotropic properties)
Study: 6112039
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of pirbuterol
Study: 6112039
Drug: Incremental doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Incremental doses of pirbuterol
Study: 27842315
Drug: Indomethacin (0.2,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (0.2, 0.1, and 0.1 mg/kg i.v. every 24 h for 3 doses)
Study: 27842315
Drug: Ibuprofen lysine
Normalized name: Ibuprofen Lysine
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen lysine (10, 5, and 5 mg/kg i.v. every 24 h for 3 doses)
Study: 21286719
Drug: Cisplatin-based chemotherapy
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin-based chemotherapy concurrent with radiotherapy
Study: 19038534
Drug: Aripiprazole 30
Normalized name: aripiprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aripiprazole 30 mg/day (immediate initiation with simultaneous discontinuation of olanzapine/risperidone)
Study: 19038534
Drug: Aripiprazole 30
Normalized name: aripiprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aripiprazole 30 mg/day (immediate initiation while tapering off olanzapine/risperidone over 14 days)
Study: 19038534
Drug: Aripiprazole 30
Normalized name: aripiprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aripiprazole 30 mg/day (titrating upwards while tapering off olanzapine/risperidone over 14 days)
Study: 19038534
Drug: Aripiprazole 30
Normalized name: aripiprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aripiprazole 30 mg/day (all groups)
Study: 17061999
Drug: FTY720 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: FTY720 2.5 mg plus full-dose cyclosporine (FDC)
Study: 17061999
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil (MMF) plus full-dose cyclosporine (FDC)
Study: 17198261
Drug: FTY720 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: FTY720 5 mg plus reduced-dose cyclosporine (RDC)
Study: 12697283
Drug: Coenzyme Q10
Normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Coenzyme Q10 (CoQ10) supplementation (360 mg daily for 4 weeks)
Study: 10521100
Drug: 3.75 mg
Normalized name: zopiclone 3.75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.75 mg i.m. dose of triptorelin
Study: 7595707
Drug: Tamoxifen (TAM;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen (TAM; 20 mg/d)
Study: 7595707
Drug: Toremifene (TOR;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toremifene (TOR; 60 mg/d)
Study: 7595707
Drug: Toremifene (TOR;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toremifene (TOR; 200 mg/d)
Study: 6161320
Drug: (‐)Deprenyl 10
Normalized name: (11C)L-deprenyl-D2
Approvals — FDA: no, EMA: no, PMDA: no
Description: (‐)Deprenyl 10 mg daily for 4 weeks
Study: 28202404
Drug: Single-dose rhC1-INH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose rhC1-INH 50 U/kg
Study: 28202404
Drug: Single-dose rhC1-INH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose rhC1-INH 2100 U
Study: 28202404
Drug: Additional doses
Normalized name: chromous chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Additional doses after initial rhC1-INH 2100 U dose (total dose, 4200-6300 U)
Study: 26272170
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (LLLT) applied on the day of separation
Study: 21525161
Drug: 17β‐estradiol 0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17β‐estradiol 0.05 mg/d
Study: 21525161
Drug: zolpidem 10
Normalized name: zolpidem 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: zolpidem 10 mg/d
Study: 17178983
Drug: Imiquimod in
Normalized name: Product containing imiquimod in cutaneous dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imiquimod in combination with meglumine antimoniate
Study: 1727882
Drug: 1% silver
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% silver sulfadiazine cream applied twice daily to the urethral meatus
Study: 6395321
Drug: Naproxen (NAP)
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naproxen (NAP) 10 mg/kg/day